Life science firm Perseon has received approval from the US Food and Drug Administration (FDA) for its MicroThermX microwave ablation system.
The approval has been granted for the specific indication of laparoscopic ablation procedures using image guidance.
Perseon CEO Clint Carnell said: "This new indication increases the type of cases that our technology will be used for and the opportunity to expand the use of MicroThermX in surgical oncology.
"This moves us closer to achieving our clinical initiatives to benefit patients, physicians, and the healthcare system worldwide."
According to the company, the MicroThermX will use precision-guided microwave energy to destroy soft tissue.
Formerly known as BSD Medical, the company develops and markets medical systems to treat cancer using heat therapy.
The firm markets its products in the US, Europe and Asia.